EU/3/08/584

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2015 on request of the sponsor.

On 3 December 2008, orphan designation (EU/3/08/584) was granted by the European Commission to Ziopharm Oncology Limited, United Kingdom, for palifosfamide for the treatment of soft tissue sarcoma.

Key facts

Active substance
Palifosfamide
Disease / condition
Treatment of soft tissue sarcoma
Date of decision
03/12/2008
Outcome
Positive
Orphan decision number
EU/3/08/584

Sponsor's contact details

Ziopharm Oncology Limited
3rd Floor
24 Chiswell Street
London EC1Y 4YX
United Kingdom
Tel. +44 (0)20 7382 1820
Fax +44 (0)20 7382 1821
E-mail: info@ziopharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating